 |
|
Reduced Ocular Allergy With Fixed-Combination 0.2% Brimonidine–0.5% Timolol—Reply
Mark B. Sherwood, MD;
E. Randy Craven, MD;
Connie Chou, PhD;
Harvey B. DuBiner, MD;
Amy L. Batoosingh, BA;
Rhett M. Schiffman, MD, MS, MHSA;
Scott M. Whitcup, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We would like to thank Dr Alvarado for his interest in our study and his very thoughtful discussion. We similarly noted the low rate of ocular allergy associated with 0.2% brimonidine–0.5% timolol fixed-combination therapy relative to 0.2% brimonidine monotherapy.1 Although the dosing regimen was twice daily for the combination product as compared with 3 times daily for brimonidine alone, we agree with Dr Alvarado's assessment that the addition of timolol appears to play an important role in the reduced allergy rate, as the rate of allergy was still well below the previous 12-month reported rates with twice daily dosing of 0.2% brimonidine.2 This study during a 12-month period should provide a realistic assessment of the overall allergy rate with . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED LETTER
Reduced Ocular Allergy With Fixed-Combination 0.2% Brimonidine–0.5% Timolol
Jorge A. Alvarado
Arch Ophthalmol. 2007;125(5):717.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Twice-Daily 0.2% Brimonidine–0.5% Timolol Fixed-Combination Therapy vs Monotherapy With Timolol or Brimonidine in Patients With Glaucoma or Ocular Hypertension: A 12-Month Randomized Trial
Mark B. Sherwood, E. Randy Craven, Connie Chou, Harvey B. DuBiner, Amy L. Batoosingh, Rhett M. Schiffman, Scott M. Whitcup, and for the Combigan Study Groups I and II
Arch Ophthalmol. 2006;124(9):1230-1238.
ABSTRACT
| FULL TEXT
|
